Bryan, Garnier & Co's News

Read all the news of the independent investment banking dedicated to Growth
Share on
Filters

Sanofi: Jury’s verdict in PCSK9 battle favours Amgen

NEUTRAL, Fair Value EUR88 (+21%)

Published last March Thursday 17, 2016

Cellectis: Collaboration with MabQuest on a new class of PD-1 mAbs

BUY, Fair Value EUR37 (+63%)

Published last March Thursday 17, 2016
Bryan Garnier confirms its Leadership in Technology and Healthcare

Bryan Garnier confirms its Leadership in Technology and Healthcare

Published last March Thursday 17, 2016

Suez: A free option?

BUY-Top Picks, Fair Value EUR19 (+20%)

Published last March Monday 14, 2016

Saint Gobain: Deal with the Burkard family extended

BUY, Fair Value EUR42 (+11%)

Published last March Monday 14, 2016

Dialog Semiconductor: Q4-15 beats, but Q1-16 revenue outlook disappointing. Looking to set up a share buy-back.

NEUTRAL, Fair Value EUR38 (+15%)

Published last March Tuesday 8, 2016

Sword Group: Final FY15 results fully in line with preliminary estimates; FY16 guidance confirmed

BUY, Fair Value EUR28 (+21%)

Published last March Tuesday 8, 2016

Engie: Rise of the phoenix?

BUY, Fair Value EUR17 vs. EUR19 (+21%)

Published last March Tuesday 8, 2016

adidas Group: FY15 results fairly in line with pre-announced items, solid FY16 outlook

BUY, Fair Value EUR104 (+5%)

Published last March Thursday 3, 2016

bioMérieux: BioMérieux still offers compelling growth profile

BUY, Fair Value EUR118 vs. EUR121 (+17%)

Published last March Thursday 3, 2016

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities